Market Cap 215.45M
Revenue (ttm) 1.41M
Net Income (ttm) -62.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,426.95%
Debt to Equity Ratio -0.55
Volume 5,165,500
Avg Vol 22,158,412
Day's Range N/A - N/A
Shares Out 148.59M
Stochastic %K 8%
Beta 0.77
Analysts Sell
Price Target $5.50

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therap...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 619 3990
Address:
111 S. Wood Avenue, Unit #100, Iselin, United States
IniG
IniG Jul. 4 at 5:52 PM
$OTLK BTIG analyst downgraded OTLK from BUY -> HOLD on 30th June, last Tuesday with price target of $1.61. That's the day share price started to pull back. DO remember that BTIG was the ATM broker for OTLK till May 2026. OTLK terminated its contract and now H.C. Wainwright is its broker. Of course, BTIG analyst is very honest and this contract termination has no negative impact on his analysis. 😉
1 · Reply
nbkt88e
nbkt88e Jul. 4 at 4:10 PM
1 · Reply
satrasal
satrasal Jul. 4 at 4:05 PM
$OTLK Of 16 mil shorts, 3 were between 1.5 and 2, and 13 under .5. Jun1-15, about 2.5 mil shorts covered (.7 to .9) before the jun16 fda resub accepted PR. Otlk then ran 1.2 to 1.8 jun 16-22. The spike to 1.88 was on jun 22 with borrow rate at 10-12% and only on jun 24 around 1pm did borr spike to 100%; by jun 26morning borr was down to 17%. So my guess is shorts entered in the 1.8 to 1.7 range june 22-24, and depleted inventory enough to raise rates, though there was 2 mil short shares availability. There might have been simultaneous profit taking as price seemed toppy, and some shorts covered as well, in the 1.55-1.65 causing borrow to fall back to 10. Whats interesting is the fact that borrow depleted enough to spike rates, implying inventory is relatively thin, which points to closely held shares, despite warrants and cheap shares in recent financings. If borr starts an uptick now we can infer shorting in the 1.4 to 1.6 as well, the last few days https://chartexchange.com/symbol/nasdaq-otlk/borrow-fee/
0 · Reply
Bobwith1o
Bobwith1o Jul. 4 at 2:50 PM
$OTLK speculation that the recent selling has been Outlook itself firing up the ATM, I’ve also heard that it is shorting. Does anybody have any recent shorting numbers and how they have changed?
0 · Reply
texmade2
texmade2 Jul. 4 at 2:44 PM
$OTLK Target 1: 0.81 cents 1.45, at resistance, Support Below : at 0.81 cents
0 · Reply
MABMAN
MABMAN Jul. 4 at 1:11 PM
$OTLK More juice for the epic "Battle of $1.70" Happy Independence Day!!
0 · Reply
SteelerJon
SteelerJon Jul. 4 at 11:48 AM
$OTLK Happy 4th of July to the USA. 250 years!!😎🇺🇸🇺🇸🇺🇸
0 · Reply
Vincybull
Vincybull Jul. 4 at 10:00 AM
$OTLK With approval, what price level could the stock reach? It could reach $3.
2 · Reply
MilkingAlgosEveryMonday
MilkingAlgosEveryMonday Jul. 4 at 6:42 AM
0 · Reply
Bobtruth
Bobtruth Jul. 4 at 4:07 AM
2 · Reply
Latest News on OTLK
Outlook Therapeutics Proxy statement: Proxy filing

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

Outlook Therapeutics Proxy statement: Proxy filing


Outlook Therapeutics Proxy statement: Proxy filing

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

Outlook Therapeutics Proxy statement: Proxy filing


Outlook Therapeutics Proxy statement: Proxy filing

May 22, 2026, 8:00 AM EDT - 6 weeks ago

Outlook Therapeutics Proxy statement: Proxy filing


Outlook Therapeutics downgraded to Neutral from Buy at BTIG

2026-05-18T10:10:08.000Z - 6 weeks ago

Outlook Therapeutics downgraded to Neutral from Buy at BTIG


Outlook Therapeutics Quarterly report: Q2 2026

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Outlook Therapeutics Quarterly report: Q2 2026


Outlook Therapeutics Earnings release: Q2 2026

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Outlook Therapeutics Earnings release: Q2 2026


Outlook Therapeutics Announces Proposed Public Offering

Mar 23, 2026, 5:30 PM EDT - 3 months ago

Outlook Therapeutics Announces Proposed Public Offering


Outlook Therapeutics Quarterly report: Q1 2026

Feb 17, 2026, 8:00 AM EST - 4 months ago

Outlook Therapeutics Quarterly report: Q1 2026


Outlook Therapeutics Earnings release: Q1 2026

Feb 17, 2026, 8:00 AM EST - 4 months ago

Outlook Therapeutics Earnings release: Q1 2026


Outlook Therapeutics sumbits Type A meeting request to FDA

2026-02-11T13:50:19.000Z - 5 months ago

Outlook Therapeutics sumbits Type A meeting request to FDA


Outlook Therapeutics Proxy statement: Proxy Filing

Jan 26, 2026, 7:00 AM EST - 5 months ago

Outlook Therapeutics Proxy statement: Proxy Filing


Outlook Therapeutics Proxy statement: Proxy Filing

Jan 26, 2026, 7:00 AM EST - 5 months ago

Outlook Therapeutics Proxy statement: Proxy Filing


Outlook Therapeutics Announces New Employment Inducement Grants

Dec 26, 2025, 5:00 PM EST - 6 months ago

Outlook Therapeutics Announces New Employment Inducement Grants


Outlook Therapeutics Annual report: Q4 2025

Dec 19, 2025, 8:30 AM EST - 7 months ago

Outlook Therapeutics Annual report: Q4 2025


Outlook Therapeutics Earnings release: Q4 2025

Dec 19, 2025, 8:30 AM EST - 7 months ago

Outlook Therapeutics Earnings release: Q4 2025


Outlook Therapeutics Provides Update on Type A Meeting with FDA

Sep 29, 2025, 8:45 AM EDT - 9 months ago

Outlook Therapeutics Provides Update on Type A Meeting with FDA


Outlook Therapeutics Requests Type A Meeting with FDA

Sep 2, 2025, 8:35 AM EDT - 10 months ago

Outlook Therapeutics Requests Type A Meeting with FDA


Outlook Therapeutics Transcript: Status Update

Aug 28, 2025, 8:30 AM EDT - 11 months ago

Outlook Therapeutics Transcript: Status Update


Outlook Therapeutics Press release: Status Update

Aug 28, 2025, 8:30 AM EDT - 11 months ago

Outlook Therapeutics Press release: Status Update


Outlook Therapeutics Quarterly report: Q3 2025

Aug 14, 2025, 12:00 AM EDT - 11 months ago

Outlook Therapeutics Quarterly report: Q3 2025


Outlook Therapeutics Earnings release: Q3 2025

Aug 14, 2025, 12:00 AM EDT - 11 months ago

Outlook Therapeutics Earnings release: Q3 2025


Outlook Therapeutics Slides: Corporate Presentation

Jul 1, 2025, 7:00 AM EDT - 1 year ago

Outlook Therapeutics Slides: Corporate Presentation


Outlook Therapeutics Transcript: Status Update

Jun 25, 2025, 12:00 PM EDT - 1 year ago

Outlook Therapeutics Transcript: Status Update


Outlook Therapeutics Earnings release: Q2 2025

May 15, 2025, 12:30 PM EDT - 1 year ago

Outlook Therapeutics Earnings release: Q2 2025


Outlook Therapeutics Quarterly report: Q2 2025

May 15, 2025, 12:30 PM EDT - 1 year ago

Outlook Therapeutics Quarterly report: Q2 2025


Outlook Therapeutics Quarterly report: Q1 2025

Feb 14, 2025, 8:00 AM EST - 1 year ago

Outlook Therapeutics Quarterly report: Q1 2025


Outlook Therapeutics Earnings release: Q1 2025

Feb 14, 2025, 8:00 AM EST - 1 year ago

Outlook Therapeutics Earnings release: Q1 2025


Outlook Therapeutics Proxy statement: Proxy Filing

Feb 10, 2025, 7:00 AM EST - 1 year ago

Outlook Therapeutics Proxy statement: Proxy Filing


Outlook Therapeutics Transcript: Study Update

Feb 3, 2025, 7:00 PM EST - 1 year ago

Outlook Therapeutics Transcript: Study Update


Outlook Therapeutics Proxy statement: Proxy Filing

Jan 31, 2025, 7:00 AM EST - 1 year ago

Outlook Therapeutics Proxy statement: Proxy Filing


IniG
IniG Jul. 4 at 5:52 PM
$OTLK BTIG analyst downgraded OTLK from BUY -> HOLD on 30th June, last Tuesday with price target of $1.61. That's the day share price started to pull back. DO remember that BTIG was the ATM broker for OTLK till May 2026. OTLK terminated its contract and now H.C. Wainwright is its broker. Of course, BTIG analyst is very honest and this contract termination has no negative impact on his analysis. 😉
1 · Reply
nbkt88e
nbkt88e Jul. 4 at 4:10 PM
1 · Reply
satrasal
satrasal Jul. 4 at 4:05 PM
$OTLK Of 16 mil shorts, 3 were between 1.5 and 2, and 13 under .5. Jun1-15, about 2.5 mil shorts covered (.7 to .9) before the jun16 fda resub accepted PR. Otlk then ran 1.2 to 1.8 jun 16-22. The spike to 1.88 was on jun 22 with borrow rate at 10-12% and only on jun 24 around 1pm did borr spike to 100%; by jun 26morning borr was down to 17%. So my guess is shorts entered in the 1.8 to 1.7 range june 22-24, and depleted inventory enough to raise rates, though there was 2 mil short shares availability. There might have been simultaneous profit taking as price seemed toppy, and some shorts covered as well, in the 1.55-1.65 causing borrow to fall back to 10. Whats interesting is the fact that borrow depleted enough to spike rates, implying inventory is relatively thin, which points to closely held shares, despite warrants and cheap shares in recent financings. If borr starts an uptick now we can infer shorting in the 1.4 to 1.6 as well, the last few days https://chartexchange.com/symbol/nasdaq-otlk/borrow-fee/
0 · Reply
Bobwith1o
Bobwith1o Jul. 4 at 2:50 PM
$OTLK speculation that the recent selling has been Outlook itself firing up the ATM, I’ve also heard that it is shorting. Does anybody have any recent shorting numbers and how they have changed?
0 · Reply
texmade2
texmade2 Jul. 4 at 2:44 PM
$OTLK Target 1: 0.81 cents 1.45, at resistance, Support Below : at 0.81 cents
0 · Reply
MABMAN
MABMAN Jul. 4 at 1:11 PM
$OTLK More juice for the epic "Battle of $1.70" Happy Independence Day!!
0 · Reply
SteelerJon
SteelerJon Jul. 4 at 11:48 AM
$OTLK Happy 4th of July to the USA. 250 years!!😎🇺🇸🇺🇸🇺🇸
0 · Reply
Vincybull
Vincybull Jul. 4 at 10:00 AM
$OTLK With approval, what price level could the stock reach? It could reach $3.
2 · Reply
MilkingAlgosEveryMonday
MilkingAlgosEveryMonday Jul. 4 at 6:42 AM
0 · Reply
Bobtruth
Bobtruth Jul. 4 at 4:07 AM
2 · Reply
AZZ_MAN
AZZ_MAN Jul. 4 at 2:40 AM
$OTLK the key question is whether these proposals are simply a precaution to maintain financing flexibility or whether the company will actually need to use them before a potential FDA decision. OTLK is seeking shareholder approval for actions that could enable both dilution and another reverse split. Specifically: * Dilution: The company is asking shareholders to approve an increase in its authorized common shares (from 260 million to 600 million) and approve the issuance of additional shares related to outstanding warrants. That would give OTLK more flexibility to raise capital, which could dilute existing shareholders. * Reverse split: Shareholders are also being asked to authorize the board to implement a reverse stock split within a range of 1-for-10 to 1-for-50, if the board decides it’s necessary, primarily to help maintain Nasdaq listing compliance. Approval does not mean the split will definitely happen—the board would still decide whether and when to implement it.
1 · Reply
adayxs
adayxs Jul. 4 at 1:42 AM
$OTLK They must be very, very careful about what they say and do. The FDA is government. Approval is all that matters.
0 · Reply
dl42
dl42 Jul. 4 at 1:23 AM
$OTLK I sure hope Bob makes an announcement around the decision to NOT do a R/S. 💥 stock starts to run!
1 · Reply
MABMAN
MABMAN Jul. 4 at 1:14 AM
$OTLK I'm less concerned about the threat of dilution than I am about weakness in negotiating power. Access to capital strenghtens leverage during what could be endgame negotiations.
3 · Reply
AnalystLLM
AnalystLLM Jul. 3 at 11:11 PM
$OTLK Bull trap, impatience, what else after 5m shares traded per day
1 · Reply
Stekli27
Stekli27 Jul. 3 at 6:55 PM
$OTLK Just a thought. OTLK has already secured approvals across Europe, including Switzerland through Swissmedic. Having worked for years in pharma manufacturing at a global CDMO, I can say Swissmedic is one of the most respected regulatory agencies in the world, with standards that are very comparable to the FDA. The FDA can certainly be more demanding in some areas, but both agencies expect high quality manufacturing, robust clinical data and strong CMC packages. That’s why I’m not losing sleep over the daily volatility. Let the science and regulators do their job. Markets overreact before binary events all the time. Patience is part of biotech investing.
1 · Reply
IniG
IniG Jul. 3 at 6:36 PM
$OTLK A reason could be the focus on US first.
3 · Reply
IniG
IniG Jul. 3 at 6:30 PM
$OTLK So OTLK is not going to be available in Ireland... 'Application Withdrawn at the Request of Applicant' https://www.sspcrs.ie/portal/rdt/pub/application/show/100056
0 · Reply
HodlCommander
HodlCommander Jul. 3 at 6:29 PM
$OTLK https://www.alphabriefing.com/otlk-twenty-six-days-to-the-fda-decision-and-the-price-target-math-nobody-is-doing/
2 · Reply
F355GTB
F355GTB Jul. 3 at 4:45 PM
$OTLK , strategy to buy cheap shares Or Shorts covering.
0 · Reply
25_usa
25_usa Jul. 3 at 4:37 PM
$OTLK Why are some people spreading fear about dilution or a reverse split? It ignores the fact that FDA approval would give $OTLK multiple financing options. 1. Revenue from LYTENAVA sales. 2. Expanded strategic partnerships or licensing deals (including Cencora support). 3. Debt financing or even a strategic acquisition once regulatory risk is removed. No one can honestly say there will be dilution or a reverse split. Those are choices, not inevitabilities. FDA approval would significantly strengthen OTLK’s position and give management better alternatives.
1 · Reply
Bobwith1o
Bobwith1o Jul. 3 at 4:24 PM
$OTLK anyone still hocking a reverse split I will consider to be a shell for the bears. No reason for a reverse split at this time.
2 · Reply